Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diphtheria-tetanus-acellular pertussis vaccine + Sabin inactivated poliovirus vaccine
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a combination vaccine containing diphtheria toxoid, tetanus toxoid, acellular pertussis antigens (DTaP), and Sabin inactivated poliovirus vaccine (Sabin-IPV). The Sabin-IPV component is produced from attenuated Sabin strains of poliovirus types 1, 2, and 3 grown on Vero cells. This combination provides immunization against diphtheria, tetanus, pertussis (whooping cough), and all three types of poliovirus. The mechanism of action involves inducing neutralizing antibodies against the respective bacterial toxins and viral antigens to confer immunity. The use of Sabin strains for IPV production reduces biosafety risks compared to wild-type virus-based IPV manufacturing. This combination has been licensed in Japan and China as part of routine childhood immunization schedules[1][2][4][8].
- Other names
- DTaP-Sabin-IPVDTP-sIPVtetravalent diphtheria-tetanus-acellular pertussis-Sabin-IPV vaccine
02
Targets
PV3 (Sabin) (Poliovirus type 3 antigen)Diphtheria toxin
Beyond the preview
Go deeper on Diphtheria-tetanus-acellular pertussis vaccine + Sabin inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Diphtheria-tetanus-acellular pertussis vaccine + Sabin inactivated poliovirus vaccine.